Ann: Positive Preliminary Results from SMARTCOUGH-C-2 Study, page-86

In my opinion its the 33% that could not be agreed upon...what disease were they a problem in agreeing...pneumonia?? bronchiolitis?? and by the way did not RAP do well in bronchiolitis in first US study?? were they not considering FDA approval for that by itself??
Having worked under US health system rules for some years before, this was always my concern..adjudication in US..I guess needed in US for FDA approval...if not my thoughts would be to send ALL results to AUS {Curtin UNI} for analyses..standardised